Evidence map›Paper›PMID 41675953›Full record

ArticleSaudi journal of medicine & medical sciences

Molecular Subtypes and Prognostic Biomarkers of Breast Carcinoma in Different Age Groups: Findings from a Tertiary Care Hospital in Saudi Arabia.

Saima Aamir, Nosheen Mahmood, Nada A Alhumrani, Wateen A Alshawi, Layan A Alyaeesh, Aseel A Alqarni, Lubna A Alagla, Sadal G Refae

Abstract read
In one paragraph

Article in Saudi journal of medicine & medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saima AamirDepartment of Pathology, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Nosheen MahmoodDepartment of Pathology, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Nada A AlhumraniKing Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Wateen A AlshawiKing Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Layan A AlyaeeshKing Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Aseel A AlqarniKing Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Lubna A AlaglaKing Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Sadal G RefaeKing Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer is a leading cause of cancer-related deaths globally, with a rising incidence in Saudi Arabia. However, limited studies from Saudi Arabia have reported the molecular subtypes and prognostic biomarkers of breast cancer. Objectives: This study aimed at comparing the clinicopathological and immunohistochemical characteristics of breast cancer among two age groups from Saudi Arabia. Methods: A retrospective study was conducted on Saudi female patients diagnosed with breast cancer between 2017 and 2022 at a tertiary care hospital in Riyadh. Patients were stratified into two age groups: aged ≤40 years and >40 years. Tumor size, grade, stage, and molecular subtypes were compared among these age groups. Results: The study comprised 300 females with breast cancer (mean age: 53.2 ± 12.6 years). Majority of patients (54.3%) were postmenopausal. The most common tumor type overall was invasive breast carcinoma of no special type (84%). In patients aged ≤40 years, most patients had T4 tumor size (39%) and were at an advanced stage (69.2%). Compared with those aged >40 years, patients aged ≤40 years had significantly higher Ki-67 index ( Conclusion: Breast cancer patients aged ≤40 years exhibited more aggressive clinicopathological features, including higher grade, advanced stage, triple negative receptor status, and poorer short-term survival compared with patients aged >40 years.

Indexed as

Breast carcinomaestrogen receptorhuman epidermal growth receptor 2progesterone receptorSaudi Arabiatriple negative breast cancer

Identifiers

PMID41675953
PMCPMC12890240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.